Atogepant for migraine.


Journal

Drugs of today (Barcelona, Spain : 1998)
ISSN: 1699-3993
Titre abrégé: Drugs Today (Barc)
Pays: Spain
ID NLM: 101160518

Informations de publication

Date de publication:
Aug 2022
Historique:
entrez: 19 8 2022
pubmed: 20 8 2022
medline: 23 8 2022
Statut: ppublish

Résumé

Atogepant is a selective oral, small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist that has been approved for preventive treatment of migraine. CGRP is a neuropeptide involved in vasodilation and cerebrovascular regulation. CGRP is the most potent vasoactive constituent of the cerebrovascular trigeminal neuronal system and has a key role in migraine. Medications targeting CGRP are being used as migraine preventive and abortive treatments.

Identifiants

pubmed: 35983926
pii: 3408815
doi: 10.1358/dot.2022.58.8.3408815
doi:

Substances chimiques

Analgesics 0
Calcitonin Gene-Related Peptide Receptor Antagonists 0
Piperidines 0
Pyridines 0
Pyrroles 0
Spiro Compounds 0
atogepant 7CRV8RR151
Calcitonin Gene-Related Peptide JHB2QIZ69Z

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

399-405

Informations de copyright

Copyright 2022 Clarivate.

Auteurs

Kate Bedrin (K)

MedStar Georgetown University Hospital, Washington, D.C., USA.

Jessica Ailani (J)

MedStar Georgetown University Hospital, Washington, D.C., USA. Jessica.x.ailani@gunet.georgetown.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH